07 jun: USA/tendens: Kina og Spanien ventes at give stigninger
07 jun: Carlsberg: Ølsalget firedobles før EM-kamp
07-06-2012 14:57:00

PRESS RELEASE: Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Powerful New Certegra(R) Informatics Workstation launched at SIIM 2012

Intended for U.S. Media Only

PR Newswire

TARRYTOWN, N.Y., June 7, 2012

TARRYTOWN, N.Y., June 7, 2012 /PRNewswire/ -- Bayer Radiology & Interventional announced the introduction of the Certegra(R) Workstation, an informatics-driven, touch--screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management(TM) applications and a new P3T(R) 2.0 operating environment. The new Workstation will be presented at the annual meeting of the Society for Imaging Informatics in Medicine (SIIM) 2012 June 7 - 12 in Orlando, FL. Following the initial launch in the U.S. and Canada, the Workstation will be rolled out in phases in markets around the world.

The Workstation serves as a single interface for radiology technologists, enabling them to provide improved patient care from study set-up and preparation to administration of the patient's study. It will be the cornerstone of Bayer's industry-first[1] Contrast Dose Management solution and informatics platform. In establishing and uploading the patient's contrast-injection record, the Workstation imports patient data directly from the Modality Work List -- reducing manual entry errors to the patient record.

"Today's technology-driven CT suite demands timely access to reliable contrast-dose records throughout the chain of care," said Anthony Cinalli, vice president of the informatics business at Bayer Radiology & Interventional. "Enabling a single workflow-centralized interface, the Workstation allows for fewer clicks, less manual entry and greater control over the quality and consistency of patient care."

Interfacing with Medrad Stellant(R) CT injection systems, the Workstation's comprehensive suite of software options provides physicians and healthcare professionals instant access to real-time actionable CT contrast data captured at the point of care enabling benefits including:

-- Reduce sub-diagnostic studies, unnecessary rescans and associated

radiation exposure[2] [3],(P3T 2.0 for personalized CT abdominal, cardiac

and pulmonary angiography studies)

-- Enable more complete diagnostic decisions (PACS Outbound Interface)

-- Speed-up radiology report turnaround time and create greater study-volume

bandwidth (RIS and SR Outbound Interfaces)

-- Improve department performance by trending, reporting and analyzing

actionable data with pinpoint accuracy (Informatics Starter Package, and

the Data Analysis and Reporting Tool)

Bayer HealthCare will have the Certegra(R) Workstation on display at its booth at SIIM 2012 (booth #217 - 221).

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

[1] Reference on file.

[2] Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible, MD, PhD. Study supported by MEDRAD Inc.

[3] 510(k) FDA clearance number: K082905

SOURCE Bayer HealthCare

/CONTACT: Karen Sutherland, +1-973-487-2113, karen.sutherland@bayer.com or Alicia Cafardi, +1-724-940-8621, alicia.cafardi@bayer.com

/Web site: http://www.bayerhealthcare.com/

(END) Dow Jones Newswires

June 07, 2012 08:57 ET (12:57 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
25 apr
PNDORA
Her er de aktier der har min opmærksomhed... Bemærk en gang iskoldt overblik og common sense er i sp..
29
27 apr
BAVA
Det er naturligvis helt valide overvejelser du gør dig, og man burde faktisk gøre sig lignende overv..
19
24 apr
BAVA
  Tirsdag 25/4 generalforsamling Torsdag den 4/5 Q1 regnskab   Vi har den 1/5 om fire børsdage, ge..
18
23 apr
PNDORA
  Det meste tyder i mine øjne på, at Pandora showet fortsætter næste uge med nye fald.       Jeg ove..
17
22 apr
 
Manden kommer med noget helt reelt, som kan diskuteres. I stedet bliver der svaret på sædvanlig EI ..
17
25 apr
 
Den stenrige Baron lå for døden. Men han nåede at få solgt alle sine aktier og lavede en aftale med ..
16
23 apr
OMXC25
Har i bemærket, at de skribenter, der skriver de værste svinere, har fået flest grønne tommelfingre?..
16
26 apr
ZEAL
Den kommer her Jacob - og da ganske interessant læsning! Zealand-chef løfter sløret for markedsføri..
13
27 apr
E:THIN
Dette kunne godt gå hen at blive stort. Alene det at iOS (iPhone, iPad) and Android nævnes.   http:/..
12
26 apr
BAVA
191 deltagere i generalforsamlingen, eller 20 pct af aktiekapitalen.  Jeg tænkte "wauw", så er alle ..
12

DSV/Nykredit: Kursmål bliver hævet med 8 pct. før regnskab

28-04-2017 14:21:41
Nykredit hæver kursmålet for DSV-aktien til 400 kr. fra 370 kr. forud for transportkoncernens regnskab i næste uge.Banken vurderer, at DSV står stærkt på markedet og kan begynde at fokusere på organisk vækst, efter at det seneste år primært er gået med at integrere amerikanske UTI Worldwide, der blev købt sidste år for 9,5 mia. kr.- Vi har hævet vores estimater for de kommende år. Derudover har vi..

Novo/Nordea: Sanofi-regnskab indikerer lyspunkt på vækstmarkeder

28-04-2017 11:31:07
Kvartalsregnskabet fra Novo Nordisks store franske rival, Sanofi, vidner om, at diabetesforretningen har haft en en stærk udvikling på vækstmarkederne, mens salget er under pres i USA.Og det er en tendens, som Nordea regner med også kan slå igennem i Novos regnskabstal på onsdag. Det fremgår af et notat.Nordea understreger dog, at det langt fra er ligetil at drage paralleller fra Sanofis regnskab...

Novo-rival slår overskuds- og salgsforventninger i første kvartal - NY

28-04-2017 08:06:11
Den franske medicinalvirksomhed Sanofi, der er blandt Novo Nordisks største konkurrenter, er kommet ud af årets første tre måneder med en bedre indtjening end ventet.I første kvartal endte det justerede overskud per aktie (Business EPS, red.) på 1,42 euro, hvilket var højere end de 1,26 euro, som analytikerne ifølge Bloomberg News havde sat næsen op efter.Den samlede omsætning steg til 8,65 mia. e..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Zealand Pharma får 8 mio. kr. i royalty-betaling i første kvartal
2
Novo/Nordea: Sanofi-regnskab indikerer lyspunkt på vækstmarkeder
3
Aktier/tendens: Danske Bank sætter dagsordenen
4
Mærsk sætter pris på kæmpe tysk opkøb - NY
5
Aktier/åbning: Danske Bank tager teten efter regnskabstriumf

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
29. april 2017 05:40:56
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseCandidateBuild_20170427.1 - EUROWEB5 - 2017-04-29 05:40:56 - 2017-04-29 05:40:56 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x